Home / Petrochemicals / Neuroendocrine Carcinoma Global Clinical Trials Review, H1, 2015

Neuroendocrine Carcinoma Global Clinical Trials Review, H1, 2015

Published: Mar 2015 | No Of Pages: 65 | Published By: GlobalData

Neuroendocrine Carcinoma Global Clinical Trials Review, H1, 2015

Summary

GlobalData's clinical trial report, “Neuroendocrine Carcinoma Global Clinical Trials Review, H1, 2015" provides data on the Neuroendocrine Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuroendocrine Carcinoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuroendocrine Carcinoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Neuroendocrine Carcinoma 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Neuroendocrine Carcinoma to Oncology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by Phase 17
In Progress Trials by Phase 18
Clinical Trials by Trial Status 19
Clinical Trials by End Point Status 20
Unaccomplished Trials of Neuroendocrine Carcinoma 21
Subjects Recruited Over a Period of Time 22
Clinical Trials by Sponsor Type 23
Prominent Sponsors 24
Top Companies Participating in Neuroendocrine Carcinoma Therapeutics Clinical Trials 25
Prominent Drugs 26
Clinical Trial Profiles 27
Clinical Trial Overview of Top Companies 27
Pfizer Inc. 27
Clinical Trial Overview of Pfizer Inc. 27
Novartis AG 28
Clinical Trial Overview of Novartis AG 28
Philogen S.p.A. 29
Clinical Trial Overview of Philogen S.p.A. 29
Clinical Trial Overview of Top Institutes / Government 30
National Cancer Institute 30
Clinical Trial Overview of National Cancer Institute 30
The University of Texas M. D. Anderson Cancer Center 31
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 31
Fondazione IRCCS - Istituto Nazionale dei Tumori 32
Clinical Trial Overview of Fondazione IRCCS - Istituto Nazionale dei Tumori 32
Japan Clinical Oncology Group 33
Clinical Trial Overview of Japan Clinical Oncology Group 33
Alberta Health Services 34
Clinical Trial Overview of Alberta Health Services 34
Centre Hospitalier Universitaire de Grenoble 35
Clinical Trial Overview of Centre Hospitalier Universitaire de Grenoble 35
Chiba University 36
Clinical Trial Overview of Chiba University 36
Gabrail Cancer Center 37
Clinical Trial Overview of Gabrail Cancer Center 37
Five Key Clinical Profiles 38
Appendix 63
Abbreviations 63
Definitions 63
Research Methodology 64
Secondary Research 64
About GlobalData 65
Contact Us 65
Disclaimer 65
Source 65

List of Tables
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials by Region, 2015* 7
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 10
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Neuroendocrine Carcinoma Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 13
Proportion of Neuroendocrine Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2015* 14
Neuroendocrine Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 15
Neuroendocrine Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 16
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials by Phase, 2015* 17
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 18
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2015* 19
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2015* 20
Neuroendocrine Carcinoma Therapeutics, Global, Suspended Clinical Trials, 2015* 21
Neuroendocrine Carcinoma Therapeutics, Global, Withdrawn Clinical Trials, 2015* 21
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 22
Neuroendocrine Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 23
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 24
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 25
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 26
Neuroendocrine Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2015* 27
Neuroendocrine Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2015* 28
Neuroendocrine Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Philogen S.p.A., 2015* 29
Neuroendocrine Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2015* 30
Neuroendocrine Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2015* 31
Neuroendocrine Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Fondazione IRCCS - Istituto Nazionale dei Tumori, 2015* 32
Neuroendocrine Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Japan Clinical Oncology Group, 2015* 33
Neuroendocrine Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Alberta Health Services, 2015* 34
Neuroendocrine Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Centre Hospitalier Universitaire de Grenoble, 2015* 35
Neuroendocrine Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Chiba University, 2015* 36
Neuroendocrine Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Gabrail Cancer Center, 2015* 37

List of Figures
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials by Region (%), 2015* 7
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2015* 10
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Neuroendocrine Carcinoma Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Proportion of Neuroendocrine Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2015* 14
Neuroendocrine Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 15
Neuroendocrine Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 16
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials by Phase (%), 2015* 17
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 18
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2015* 19
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2015* 20
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 22
Neuroendocrine Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 23
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 24
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 25
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 26
GlobalData Methodology 64

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +